Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Marine natural products provide a rich source of drug leads. Using selected examples, Molinski and colleagues review the history of marine natural drug development, examine the unique challenges in this field, and discuss recent advances that may expand the promise of 'drugs from the sea'.
This Opinion highlights some of the recent failures in the clinical trials of chemokine receptor antagonists, explores possible reasons as to why these might have occurred and looks at potential solutions to generate effective chemokine receptor antagonist therapeutics.
The US FDA can now require companies to develop a risk evaluation and mitigation strategy (REMS) for therapeutic products. Bethan Hughes investigates the recent evolution of risk-management strategies in drug development.
Dissection of the signalling pathways mediating apoptosis — controlled cell death — in cancer, inflammation and neurodegenerative disorders has stimulated the discovery of a wealth of potential drugs to target this process.